Bear pressure on Viking Therapeutics is "winning by share performance metric," but it is based on "fears and alternative facts," H.C. Wainwright analyst Joseph Pantginis tells investors in a research note. He believes Viking's shares are not reflecting the "compelling data" delivered to date for VK2809, as well as VK5211. The "massive" short interest, currently about 45% of shares outstanding, has been putting "significant pressure on the shares following highly positive news events," says Pantginis. The analyst continues to believe VK2809 represents a potential best-in-class molecule that could "also benefit from the clear definition of regulatory paths and questions established by others." He reiterates a Buy rating on Viking Therapeutics with a $31 price target.